News for Healthier Living
Espervita's EVT0185 Demonstrates Reversal of Metabolic Dysfunction and Liver Fibrosis in Cell Metabolism Publication
Espervita Therapeutics, a biotechnology company developing targeted metabolic reprogramming therapies, announced the publication in Cell Metabolism of groundbreaking preclinical data demonstrating that its lead compound, EVT0185, a first-in-class dual inhibitor of ATP citrate lyase (ACLY) and acetyl-CoA synthetase 2 (ACSS2), resolves Metabolic Dysfunction-Associated Steatohepatitis (MASH) and liver fibrosis while simultaneously reducing blood glucose and cholesterol. Unlike current therapies that reduce liver fat without directly inhibiting the hepatic stellate cells (HSCs) responsible for fibrosis, EVT0185 acts within the liver to directly reprogram fundamental metabolic pathways in both HSCs and hepatocytes, targeting the shared drivers of MASH fibrosis and metabolic dysfunction.
January 6, 2026
January 8 2026January 7 2026January 6 2026 - DeepCodon: A Rare-Codon-Aware AI Tool Boosts Protein Expression in E. Coli
- Engineered Probiotics Emerge as Programmable Living Medicines for Complex Diseases
- Renowned UNC Pediatric Biochemical Geneticist Leads First Study on a Novel Treatment for Hunter Syndrome
- High Levels of Chagas Disease Parasite Found in Bugs Near U.S.-Mexico Border
- AI-Powered ECG Analysis Offers Promising Path for Early Detection of Chronic Obstructive Pulmonary Disease, Says Mount Sinai Researchers
- Espervita's EVT0185 Demonstrates Reversal of Metabolic Dysfunction and Liver Fibrosis in Cell Metabolism Publication
- Neutrophil-to-Lymphocyte Ratio May Aid Risk Stratification in Depressive Disorder
- Engineered RNA Sensor Detects and Fights Coronavirus Inside Living Cells
- Advances in Maternal-Fetal and Neonatal Diagnostics Highlighted in Special January Issue of ADLM's Clinical Chemistry Journal
- Can Taking CBD Help People Smoke Less Weed?
- Noninvasive Prenatal Screening Could Prevent Permanent Hearing Loss in Newborns
- U.S. Cuts Recommended Childhood Vaccines
- Nearly 3,000 Pounds of Ground Beef Recalled for Possible E. coli
- U.S. Backs At-Home HPV Testing to Boost Cervical Cancer Screening
- Novo Nordisk Launches Daily Weight-Loss Pill to Expand GLP-1 Access
- Young Adults With IBD Face Insurance, Cost Barriers To Care, Survey Finds
- Fingerprick Blood Test Accurately Assesses Signs of Alzheimer's, Researchers Say
- Food Insecurity, Financial Struggles Increase Children's Risk of Long COVID
- Hormone Drug Helps Fight Hormone-Fueled Breast Cancer, Trial Shows
- Autism Therapy Centers Targeted By Private Equity In U.S., Study Reveals
- Teens' Smartphone Use At School Exceeds An Hour Daily, Tracking App Reveals
- First Patients Enrolled in Groundbreaking Brain Cancer Study at Nationally Recognized Academic Medical Center
- 10 Years Later, First Children's Hospital Los Angeles Patient to Receive CAR T-Cell Therapy Remains Cancer-Free
- A Repurposed Drug Duo Shows Powerful Synergy Against Liver Fibrosis
- CU Scientists Use Ultrasound to Make Tumor Treatment Easier--and Less Risky
January 5 2026January 4 2026January 3 2026January 2 2026January 1 2026December 31 2025December 30 2025December 29 2025December 28 2025December 27 2025December 26 2025
|
|
|
|
|